Status:
TERMINATED
Blood Samples to Identify Biomarkers of Busulfan
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
University of Washington
Seattle Children's Hospital
Conditions:
Leukemia
Lymphoma
Eligibility:
All Genders
Brief Summary
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by met...
Detailed Description
The long-range goal of this work is to improve overall survival in hematopoietic stem cell transplant (HCT) recipients by personalizing their conditioning regimen and/or intravenous (IV) busulfan (BU)...
Eligibility Criteria
Inclusion
- Scheduled to receive targeted intravenous busulfan (any dose, any number of doses, any dosing frequency) as part of their hematopoietic stem cell transplant conditioning;
- Weight \> 21kg.
Exclusion
- Unable to read English;
- Female patients who are pregnant or breastfeeding;
- Life expectancy severely limited by diseases other than malignancy.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 7 2024
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT02291965
Start Date
November 1 2014
End Date
October 7 2024
Last Update
March 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98105